Activation of multiple effector mechanisms to enhance tumor lmmunotherapy

J. A. Hank, M. R. Albertini, J. Schiller, P. M. Sondel

Research output: Contribution to journalArticlepeer-review

14 Scopus citations


Recent technical advances have enabled the generation of clinical reagents for immunotherapy. Currently, treatment protocols combining both interleukin-2 (IL-2) and tumor-specific monoclonal antibody are underway at the University of Wisconsin Comprehensive Cancer Center and elsewhere. These approaches are based on the hypothesis that IL-2-activated lymphocytes will use tumor-reactive antibody to more selectively and effectively destroy tumor in vivo. Just as IL-2 can activate lymphocytes to destroy antibody-coated tumor cells, other agents can activate neutrophils and monocytes to destroy antibody-treated tumor cells. We are investigating, in the laboratory and clinic, approaches aimed at eventually using combinations of distinct antibody- based tumor recognition mechanisms in patients whose monocytes, neutrophils, and lymphocytes have been simultaneously activated with multiple biologic agents.

Original languageEnglish (US)
Pages (from-to)329-335
Number of pages7
JournalJournal of Immunotherapy
Issue number4
StatePublished - Nov 1993


  • Combination immunotherapy
  • Interleukin-2
  • Monoclonal antibody

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Pharmacology
  • Cancer Research


Dive into the research topics of 'Activation of multiple effector mechanisms to enhance tumor lmmunotherapy'. Together they form a unique fingerprint.

Cite this